ArticleCirculation. Heart failure2018
Acute and Chronic Increases of Circulating FSTL1 Normalize Energy Substrate Metabolism in Pacing-Induced Heart Failure.
Open access · bronzeAbstract read
In one paragraph
Article in Circulation. Heart failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- FSTL-1 as a Novel Cardiokine of Cardiac Angiogenesis: A Systematic Review.Vascular health and risk management · 2025Pooled it
- Human multi-tissue transcriptomics identifies galectin-1 and follistatin-like 1 as exerkines with distinct transcript-to-serum coupling after exercise.The Journal of physiology · 2026Article
- Signalling pathways regulated by FSTL1 in inflammation and potential therapeutic applications (Review).International journal of molecular medicine · 2026Review
- Activating the Osteoblastic USP26 Pathway Alleviates Multi-Organ Fibrosis by Decreasing Insulin Resistance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Skeletal muscle-heart crosstalk in chronic kidney disease: hierarchical signaling networks underlying myocardial metabolic reprogramming and fibrotic remodeling.Frontiers in physiology · 2026Review
- Impacts of systemic milieu on cerebrovascular and brain aging: insights from heterochronic parabiosis, blood exchange, and plasma transfer experiments.GeroScience · 2025Review
- Sodium-glucose co-transporter 2 inhibitors: Prospects for canine myxomatous mitral valve disease and finding the "right drug" and the "right dose" for dogs.The Journal of veterinary medical science · 2025Review
- Decoding the Liver-Heart Axis in Cardiometabolic Diseases.Circulation research · 2025Review
- Skeletal Muscle as Endocrine Organ.Advances in experimental medicine and biology · 2025Review
- Impact of follistatin-like 1 on cardiac repair processes following myocardial infarction.Frontiers in cell and developmental biology · 2025Review
- Follistatin-like 1: a novel biomarker with a potential link to obstructive sleep apnea severity and treatment efficacy.Frontiers in endocrinology · 2025Article
- Immunomodulatory behavior of CircRNAs in tumor microenvironment.Oncology research · 2025Review
- An engineered human cardiac tissue model reveals contributions of systemic lupus erythematosus autoantibodies to myocardial injury.Nature cardiovascular research · 2024Article
- Towards Metabolomic-Based Precision Approaches for Classifying and Treating Heart Failure.JACC. Basic to translational science · 2024Review
- Follistatin-like protein 1 attenuates doxorubicin-induced cardiomyopathy by inhibiting MsrB2-mediated mitophagy.Molecular and cellular biochemistry · 2024Article
- Follistatin-like 1 (FSTL1) levels as potential early biomarker of cardiovascular disease in a Mexican population.Heart and vessels · 2024Article
- Tachycardia-induced metabolic rewiring as a driver of contractile dysfunction.Nature biomedical engineering · 2024Article
- An engineered human cardiac tissue model reveals contributions of systemic lupus erythematosus autoantibodies to myocardial injury.bioRxiv : the preprint server for biology · 2024Article
- Circulating Myokines as Novel Biomarkers for Cardiovascular Diseases.Reviews in cardiovascular medicine · 2024Review
- Circular RNAs: Promising Treatment Targets and Biomarkers of Ischemic Stroke.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 2 countries.
Mitsuru SekiFrom the Cardiovascular Research Center (M.S., J.C.P., C.K., L.K., J.J., A.P., T.W., E.M., J.Y.P., F.A.R.) and the Center for Translational Medicine (S.R.), Lewis Katz School of Medicine at Temple University, Philadelphia, PA; Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, MA (S.M., M.A.Z., C.-L.W., K.W.); Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy (F.A.R.); and Fondazione Toscana Gabriele Monasterio, Pisa, Italy (F.A.R.).
Jeffery C PowersFrom the Cardiovascular Research Center (M.S., J.C.P., C.K., L.K., J.J., A.P., T.W., E.M., J.Y.P., F.A.R.) and the Center for Translational Medicine (S.R.), Lewis Katz School of Medicine at Temple University, Philadelphia, PA; Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, MA (S.M., M.A.Z., C.-L.W., K.W.); Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy (F.A.R.); and Fondazione Toscana Gabriele Monasterio, Pisa, Italy (F.A.R.).
Sonomi MaruyamaFrom the Cardiovascular Research Center (M.S., J.C.P., C.K., L.K., J.J., A.P., T.W., E.M., J.Y.P., F.A.R.) and the Center for Translational Medicine (S.R.), Lewis Katz School of Medicine at Temple University, Philadelphia, PA; Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, MA (S.M., M.A.Z., C.-L.W., K.W.); Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy (F.A.R.); and Fondazione Toscana Gabriele Monasterio, Pisa, Italy (F.A.R.).
Maria A ZuriagaFrom the Cardiovascular Research Center (M.S., J.C.P., C.K., L.K., J.J., A.P., T.W., E.M., J.Y.P., F.A.R.) and the Center for Translational Medicine (S.R.), Lewis Katz School of Medicine at Temple University, Philadelphia, PA; Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, MA (S.M., M.A.Z., C.-L.W., K.W.); Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy (F.A.R.); and Fondazione Toscana Gabriele Monasterio, Pisa, Italy (F.A.R.).
Chia-Ling WuFrom the Cardiovascular Research Center (M.S., J.C.P., C.K., L.K., J.J., A.P., T.W., E.M., J.Y.P., F.A.R.) and the Center for Translational Medicine (S.R.), Lewis Katz School of Medicine at Temple University, Philadelphia, PA; Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, MA (S.M., M.A.Z., C.-L.W., K.W.); Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy (F.A.R.); and Fondazione Toscana Gabriele Monasterio, Pisa, Italy (F.A.R.).
Clara KurishimaFrom the Cardiovascular Research Center (M.S., J.C.P., C.K., L.K., J.J., A.P., T.W., E.M., J.Y.P., F.A.R.) and the Center for Translational Medicine (S.R.), Lewis Katz School of Medicine at Temple University, Philadelphia, PA; Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, MA (S.M., M.A.Z., C.-L.W., K.W.); Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy (F.A.R.); and Fondazione Toscana Gabriele Monasterio, Pisa, Italy (F.A.R.).
Lydia KimFrom the Cardiovascular Research Center (M.S., J.C.P., C.K., L.K., J.J., A.P., T.W., E.M., J.Y.P., F.A.R.) and the Center for Translational Medicine (S.R.), Lewis Katz School of Medicine at Temple University, Philadelphia, PA; Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, MA (S.M., M.A.Z., C.-L.W., K.W.); Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy (F.A.R.); and Fondazione Toscana Gabriele Monasterio, Pisa, Italy (F.A.R.).
Jesse JohnsonFrom the Cardiovascular Research Center (M.S., J.C.P., C.K., L.K., J.J., A.P., T.W., E.M., J.Y.P., F.A.R.) and the Center for Translational Medicine (S.R.), Lewis Katz School of Medicine at Temple University, Philadelphia, PA; Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, MA (S.M., M.A.Z., C.-L.W., K.W.); Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy (F.A.R.); and Fondazione Toscana Gabriele Monasterio, Pisa, Italy (F.A.R.).
Anthony PoidomaniFrom the Cardiovascular Research Center (M.S., J.C.P., C.K., L.K., J.J., A.P., T.W., E.M., J.Y.P., F.A.R.) and the Center for Translational Medicine (S.R.), Lewis Katz School of Medicine at Temple University, Philadelphia, PA; Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, MA (S.M., M.A.Z., C.-L.W., K.W.); Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy (F.A.R.); and Fondazione Toscana Gabriele Monasterio, Pisa, Italy (F.A.R.).
Tao WangFrom the Cardiovascular Research Center (M.S., J.C.P., C.K., L.K., J.J., A.P., T.W., E.M., J.Y.P., F.A.R.) and the Center for Translational Medicine (S.R.), Lewis Katz School of Medicine at Temple University, Philadelphia, PA; Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, MA (S.M., M.A.Z., C.-L.W., K.W.); Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy (F.A.R.); and Fondazione Toscana Gabriele Monasterio, Pisa, Italy (F.A.R.).
Eric MuñozFrom the Cardiovascular Research Center (M.S., J.C.P., C.K., L.K., J.J., A.P., T.W., E.M., J.Y.P., F.A.R.) and the Center for Translational Medicine (S.R.), Lewis Katz School of Medicine at Temple University, Philadelphia, PA; Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, MA (S.M., M.A.Z., C.-L.W., K.W.); Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy (F.A.R.); and Fondazione Toscana Gabriele Monasterio, Pisa, Italy (F.A.R.).
Sudarsan RajanFrom the Cardiovascular Research Center (M.S., J.C.P., C.K., L.K., J.J., A.P., T.W., E.M., J.Y.P., F.A.R.) and the Center for Translational Medicine (S.R.), Lewis Katz School of Medicine at Temple University, Philadelphia, PA; Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, MA (S.M., M.A.Z., C.-L.W., K.W.); Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy (F.A.R.); and Fondazione Toscana Gabriele Monasterio, Pisa, Italy (F.A.R.).
Joon Y ParkFrom the Cardiovascular Research Center (M.S., J.C.P., C.K., L.K., J.J., A.P., T.W., E.M., J.Y.P., F.A.R.) and the Center for Translational Medicine (S.R.), Lewis Katz School of Medicine at Temple University, Philadelphia, PA; Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, MA (S.M., M.A.Z., C.-L.W., K.W.); Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy (F.A.R.); and Fondazione Toscana Gabriele Monasterio, Pisa, Italy (F.A.R.).
Kenneth WalshFrom the Cardiovascular Research Center (M.S., J.C.P., C.K., L.K., J.J., A.P., T.W., E.M., J.Y.P., F.A.R.) and the Center for Translational Medicine (S.R.), Lewis Katz School of Medicine at Temple University, Philadelphia, PA; Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, MA (S.M., M.A.Z., C.-L.W., K.W.); Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy (F.A.R.); and Fondazione Toscana Gabriele Monasterio, Pisa, Italy (F.A.R.).
Fabio A RecchiaFrom the Cardiovascular Research Center (M.S., J.C.P., C.K., L.K., J.J., A.P., T.W., E.M., J.Y.P., F.A.R.) and the Center for Translational Medicine (S.R.), Lewis Katz School of Medicine at Temple University, Philadelphia, PA; Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, MA (S.M., M.A.Z., C.-L.W., K.W.); Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy (F.A.R.); and Fondazione Toscana Gabriele Monasterio, Pisa, Italy (F.A.R.). fabio.recchia@temple.edu.
Boston University · USScuola Superiore Sant'Anna · IT
Funding
Follistatin-like protein 1 in cardiac and systemic metabolismR01HL129120 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI RECCHIA, FABIO A, WALSH, KENNETH · 2016 to 2019
$2.9MFunctional implications of fluid shear stress-induced mitochondrial remodelingR01HL126952 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI PARK, JOON YOUNG · 2015 to 2019
$2.1MInflammatory Wnt signaling in ischemic myocardiumR01HL131006 · NHLBI · UNIVERSITY OF VIRGINIA · PI WALSH, KENNETH · 2016 to 2019
$2.1MMyokine Control of Hepatic SteatosisR21AG052160 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI WALSH, KENNETH · 2016 to 2017
$452kNHLBI NIH HHS R01 HL126952NHLBI NIH HHS R01 HL129120NHLBI NIH HHS R01 HL131006NIA NIH HHS R21 AG052160
Abstract
backgroundFSTL1 (follistatin-like protein 1) is an emerging cardiokine/myokine that is upregulated in heart failure (HF) and is found to be cardioprotective in animal models of cardiac injury. We tested the hypothesis that circulating FSTL1 can affect cardiac function and metabolism under baseline physiological conditions and in HF. METHODS AND
resultsFSTL1 was acutely (10 minutes) or chronically (2 weeks) infused to attain clinically relevant blood levels in conscious dogs with cardiac tachypacing-induced HF. Dogs with no cardiac pacing and FSTL1 infusion served as control.
conclusionsThese findings support a novel function for FSTL1 and provide the first direct evidence that a circulating cardiokine/myokine can alter myocardial and systemic energy substrate metabolism, in vivo.
Indexed as
AnimalsBlood PressureCardiac Pacing, ArtificialDisease Models, AnimalDogsDrug Administration ScheduleFatty Acids, NonesterifiedFollistatin-Related ProteinsGlucoseHeart FailureKetone BodiesMaleOxygen ConsumptionVascular ResistanceFatty Acids, NonesterifiedFollistatin-Related ProteinsGlucoseKetone Bodiesanimalsglucoseheartheart failuremyocardium
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.